T cell receptor for antigen recognition (TCR, CD8+ cytotoxic T cell type) (TCR (CD8+))

The T cell receptor (TCR) on cytotoxic CD8+ T cells recognizes short peptide fragments derived from intracellular proteins and presented on tumor cell surfaces by MHC class I molecules[1][2][5][6][8]. CD8 acts as a co-receptor, stabilizing the interaction and enhancing sensitivity for antigen recognition[1][4][6]. Upon binding to tumor antigen-MHC complexes, the TCR/CD8 interaction triggers cellular signaling cascades, resulting in the release of cytolytic molecules (perforin, granzymes) that induce targeted tumor cell death[1][5][8]. This mechanism is central to cancer immunosurveillance and is leveraged in immunotherapies, though tumor microenvironments and suppressive factors (e.g., myeloid-derived suppressor cells) can interfere with antigen-specific response and contribute to cancer immune escape[3][7][8].

Other names

CD8+ T cell receptor (CD8+ TCR)Cytotoxic T lymphocyte TCRCTL TCR

Recognition of tumor antigens presented on MHC class I by TCR/CD8 leads to activation, cytokine release, and targeted cell killing via granzymes and perforin[1][2][5][8]. Checkpoint inhibitors work by blocking inhibitory signals (e.g., PD-1/PD-L1, CTLA-4) that dampen TCR-mediated recognition and killing of tumor cells[5].